Gene-Editing Beyond CRISPR

james hebrew July 20, 2022

With the approval of HUMULIN®, the first genetically modified drug, scientific community has made significant progress in developing gene edited therapies based on programmable nucleases, such as ZFNs, TALENs, EMNs and CRISPR.   London   Roots Analysis has announced the addition of “Gene-Editing Beyond CRISPR: Focus on ZFN, TALENs and Meganucleases Market, 2021-2035” report to […]